Does microdosing a GLP-1 actually work?

"Microdosing" a GLP-1 means using a fraction of the standard weight-loss dose — the idea being to capture metabolic and craving benefits while sidestepping nausea, muscle loss, and the "I feel nothing" flatness some report at full doses. It is genuinely popular right now, but the evidence base is thin, and it is worth being precise about who actually says what.

The most credible proponent is Dr. Ben Bikman (a metabolic scientist) on Rhonda Patrick's channel. He frames microdosing not as a permanent weight-loss strategy but as a roughly 90-day tool, combined with behavioral coaching, to help people rewire cravings for refined carbohydrates — then taper off. Dr. Craig Koniver (via Huberman) similarly describes microdosing semaglutide or tirzepatide to retain benefits while limiting side effects like muscle loss.

A caution on sourcing: a lot of the loudest microdosing advocacy comes from figures like Dr. Tyna Moore (via Diary of a CEO and Hyman), who treats the drug "like a hormone" and cycles doses. These are individual practitioner views popular in wellness circles — not consensus positions, and not backed by large randomized trials. Notably, despite the internet folklore, none of Precis's five core experts has made a rigorous case for microdosing; the supportive voices are all guests, and the strongest of them (Bikman) explicitly frames it as experimental and temporary. Bottom line: plausible mechanism, real anecdotes, no large-trial proof — a conversation to have with a prescriber, not a settled protocol.